2. Signaling Pathways
  3. Immunology/Inflammation
  4. NOD-like Receptor (NLR)
  5. NOD-like Receptor (NLR) Antagonist

NOD-like Receptor (NLR) Antagonist

NOD-like Receptor (NLR) Isoform Comparison

NOD-like Receptor (NLR) Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-155876
    NVP-DFV890
    		Antagonist 98.47%
    NVP-DFV890 (comopound 102) is a NLRP3 antagonist. NVP-DFV890 can be used for osteoarthritis research.
  • HY-147506
    NOD2 antagonist 1
    		Antagonist 99.57%
    NOD2 antagonist 1 (compound 32) is a potent and selective NOD2 antagonist with an IC50 of 5.23 μM. NOD2 antagonist 1 inhibits Muramyl dipeptide (MDP)-induced IL-8 secretion in THP-1 cells and inhibits MDP-induced IL-6, IL-10, TNF-α release in PBMCs.
  • HY-163274
    NOD1 antagonist-1
    		Antagonist
    NOD1 antagonist-1 (compound 37) exhibits an antagonistic activity towards NOD1 and a weak NOD1/NOD2 selectivity, with IC50s of 9.18 μM and 20.8 μM, respectively.
  • HY-143563
    NLRP3 antagonist 1
    		Antagonist
    NLRP3 antagonist 1 is a potent antagonist of NLRP3. NLRP3 is mainly expressed in macrophages and neutrophils and is involved in the body's intrinsic immunity against pathogenic infections and stress injury. NLRP3 antagonist 1 has the potential for the research of cancer disease (extracted from patent WO2021114691A1, compound 3).
  • HY-146034
    NOD1/2 antagonist-1
    		Antagonist
    NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC50 values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX).